NIH Reporter #5R01CA258421-05

NIH Grant for Gold-Derived Cancer Therapeutic Research

This opportunity is a research grant from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), focused on developing gold-derived therapeutic compounds for cancer therapy. - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - Project Focus: - Research on gold-based compounds targeting mitochondrial function in cancer cells - Emphasis on therapies for triple-negative breast cancer (TNBC) - Products/Services Requested: - No specific products, part numbers, or quantities listed - Solicitation is for research proposals, not product procurement - OEMs and Vendors: - No OEMs or vendors specified in the notice - Notable Requirements: - Research must focus on gold-derived drugs for TNBC - No unique technical or administrative requirements beyond the research scope - Estimated Award Amount: - $336,989 - Solicitation Number: - 5R01CA258421-05

Description

This NIH grant opportunity focuses on research involving gold-derived compounds targeting mitochondrial function in cancer therapy. The project aims to develop targeted gold-based drugs specifically for triple-negative breast cancer (TNBC). The award amount is approximately $336,989, with a project duration from August 2025 to July 2027. The funding is provided by the National Cancer Institute (NCI), part of the NIH.

View original listing